4-phenyl pyridine analogues as protein kinase inhibitors

Disclosed is a general formula (I), which are cyclically substituted 4-phenyl-pyridine derivatives, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: x is 2; Ra is H or methyl; R1 is selected from the group consisting of: carbocyclic or -alkyl-carbocyclic, wherein the carbocyclic group is cyclohexyl or cyclopentyl; heterocyclic or -alkyl-heterocyclic group, wherein the heterocyclic group is piperidine, piperazine, morpholine or pyrrolidine; aryl or -alkyl-aryl; heteroaryl or -alkyl-heteroaryl, wherein the heteroaryl group is pyridine, thiazole or thiophene; wherein any of the aforesaid carbocyclic, heterocyclic, aryl or heteroaryl groups may optionally be substituted; each R2 is independently R4, -alkyl-R4, OR4, NHR4, -NHalkyl-R4, -O-alkyl-R4, SR4, SOR4 or SO2R4; wherein R4 is a carbocyclic or heterocyclic group any of which may be further substituted; wherein the remaining substituents are as defined herein; and wherein any of the aforesaid carbocyclic groups and heterocyclic groups may be saturated or partially unsaturated, but do not include aromatic rings or non-aromatic rings fused to aromatic rings. Wherein, the specifically disclosed compounds of the specification are all as claimed in the granted parent patent.